Literature DB >> 22617649

Aspartoacylase supports oxidative energy metabolism during myelination.

Jeremy S Francis1, Louise Strande, Vladamir Markov, Paola Leone.   

Abstract

The inherited leukodystrophy Canavan disease arises due to a loss of the ability to catabolize N-acetylaspartic acid (NAA) in the brain and constitutes a major point of focus for efforts to define NAA function. Accumulation of noncatabolized NAA is diagnostic for Canavan disease, but contrasts with the abnormally low NAA associated with compromised neuronal integrity in a broad spectrum of other clinical conditions. Experimental evidence for NAA function supports a role in white matter lipid synthesis, but does not explain how both elevated and lowered NAA can be associated with pathology in the brain. We have undertaken a systematic analysis of postnatal development in a mouse model of Canavan disease that delineates development and pathology by identifying markers of oxidative stress preceding oligodendrocyte loss and dysmyelination. These data suggest a role for NAA in the maintenance of metabolic integrity in oligodendrocytes that may be of relevance to the strong association between NAA and neuronal viability. N-acetylaspartic acid is proposed here to support lipid synthesis and energy metabolism via the provision of substrate for both cellular processes during early postnatal development.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22617649      PMCID: PMC3434629          DOI: 10.1038/jcbfm.2012.66

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  37 in total

1.  Studies on the distribution of N-acetyl-L-aspartic acid in brain.

Authors:  H H TALLAN
Journal:  J Biol Chem       Date:  1957-01       Impact factor: 5.157

2.  Mild-onset presentation of Canavan's disease associated with novel G212A point mutation in aspartoacylase gene.

Authors:  Christopher G Janson; Edwin H Kolodny; Bai-Jin Zeng; Srinivasa Raghavan; Gregory Pastores; Paola Torres; Mitra Assadi; Scott McPhee; Olga Goldfarb; Beth Saslow; Andrew Freese; D J Wang; Larissa Bilaniuk; David Shera; Paola Leone
Journal:  Ann Neurol       Date:  2006-02       Impact factor: 10.422

3.  Homozygosity for mutation G212A of the gene for aspartoacylase is associated with atypical form of Canavan's disease.

Authors:  M Velinov; N Zellers; J Styles; K Wisniewski
Journal:  Clin Genet       Date:  2007-12-06       Impact factor: 4.438

Review 4.  N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction.

Authors:  J B Clark
Journal:  Dev Neurosci       Date:  1998       Impact factor: 2.984

5.  Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo.

Authors:  T E Bates; M Strangward; J Keelan; G P Davey; P M Munro; J B Clark
Journal:  Neuroreport       Date:  1996-05-31       Impact factor: 1.837

6.  Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease.

Authors:  Chikkathur N Madhavarao; Peethambaran Arun; John R Moffett; Sylvia Szucs; Sankar Surendran; Reuben Matalon; James Garbern; Diana Hristova; Anne Johnson; Wei Jiang; M A Aryan Namboodiri
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-22       Impact factor: 11.205

7.  Temporal window of metabolic brain vulnerability to concussions: mitochondrial-related impairment--part I.

Authors:  Roberto Vagnozzi; Barbara Tavazzi; Stefano Signoretti; Angela M Amorini; Antonio Belli; Marco Cimatti; Roberto Delfini; Valentina Di Pietro; Antonino Finocchiaro; Giuseppe Lazzarino
Journal:  Neurosurgery       Date:  2007-08       Impact factor: 4.654

8.  N-acetylaspartate as an acetyl source in the nervous system.

Authors:  V Mehta; M A Namboodiri
Journal:  Brain Res Mol Brain Res       Date:  1995-07

9.  Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.

Authors:  Maria Traka; Robert L Wollmann; Sonia R Cerda; Jason Dugas; Ben A Barres; Brian Popko
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

10.  Reversible decreases in N-acetylaspartate after acute brain injury.

Authors:  N De Stefano; P M Matthews; D L Arnold
Journal:  Magn Reson Med       Date:  1995-11       Impact factor: 4.668

View more
  19 in total

1.  Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy.

Authors:  Jiho Sohn; Peter Bannerman; Fuzheng Guo; Travis Burns; Laird Miers; Christopher Croteau; Naveen K Singhal; Jennifer A McDonough; David Pleasure
Journal:  J Neurosci       Date:  2017-01-11       Impact factor: 6.167

2.  Hyperperfusion of Frontal White and Subcortical Gray Matter in Autism Spectrum Disorder.

Authors:  Bradley S Peterson; Ariana Zargarian; Jarod B Peterson; Suzanne Goh; Siddhant Sawardekar; Steven C R Williams; David J Lythgoe; Fernando O Zelaya; Ravi Bansal
Journal:  Biol Psychiatry       Date:  2018-12-21       Impact factor: 13.382

Review 3.  Clinical applications involving CNS gene transfer.

Authors:  Boris Kantor; Thomas McCown; Paola Leone; Steven J Gray
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

Review 4.  A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra.

Authors:  Caroline D Rae
Journal:  Neurochem Res       Date:  2013-11-21       Impact factor: 3.996

5.  Dietary triheptanoin rescues oligodendrocyte loss, dysmyelination and motor function in the nur7 mouse model of Canavan disease.

Authors:  Jeremy S Francis; Vladimir Markov; Paola Leone
Journal:  J Inherit Metab Dis       Date:  2013-11-28       Impact factor: 4.982

6.  Transcriptional regulation of N-acetylaspartate metabolism in the 5xFAD model of Alzheimer's disease: evidence for neuron-glia communication during energetic crisis.

Authors:  Samantha Zaroff; Paola Leone; Vladimir Markov; Jeremy S Francis
Journal:  Mol Cell Neurosci       Date:  2015-03-10       Impact factor: 4.314

7.  Long-term follow-up after gene therapy for canavan disease.

Authors:  Paola Leone; David Shera; Scott W J McPhee; Jeremy S Francis; Edwin H Kolodny; Larissa T Bilaniuk; Dah-Jyuu Wang; Mitra Assadi; Olga Goldfarb; H Warren Goldman; Andrew Freese; Deborah Young; Matthew J During; R Jude Samulski; Christopher G Janson
Journal:  Sci Transl Med       Date:  2012-12-19       Impact factor: 17.956

Review 8.  Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.

Authors:  Dominic J Gessler; Guangping Gao
Journal:  Methods Mol Biol       Date:  2016

9.  Region- and age-dependent alterations of glial-neuronal metabolic interactions correlate with CNS pathology in a mouse model of globoid cell leukodystrophy.

Authors:  Tore Wergeland Meisingset; Alessandra Ricca; Margherita Neri; Ursula Sonnewald; Angela Gritti
Journal:  J Cereb Blood Flow Metab       Date:  2013-04-24       Impact factor: 6.200

10.  rAAV Gene Therapy in a Canavan's Disease Mouse Model Reveals Immune Impairments and an Extended Pathology Beyond the Central Nervous System.

Authors:  Seemin Seher Ahmed; Stefan A Schattgen; Ashley E Frakes; Elif M Sikoglu; Qin Su; Jia Li; Thomas G Hampton; Andrew R Denninger; Daniel A Kirschner; Brian Kaspar; Reuben Matalon; Guangping Gao
Journal:  Mol Ther       Date:  2016-04-04       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.